iDEL Therapeutics, a Dortmund, Germany-based biotech developing a synthetic shuttle platform for direct cytosolic delivery of therapeutic payloads into tumor cells, has raised €9 million ($10.25M) in seed funding led by BiomedVC. The platform enables pan-cancer uptake of small and large molecules, bypassing endosomal entrapment to target undruggable intracellular oncogenes. The capital will advance two proprietary lead programs—a single-domain antibody for intracellular oncogene targeting and a multicancer drug conjugate—toward clinical evaluation in solid tumors.
Seed Funding Amid Delivery Tech Surge
The round comes as intracellular delivery platforms attract capital. Entrada Therapeutics raised $175M in VC funding pre-IPO plus IPO proceeds for its ENDO peptidic platform targeting oncology among other areas. Defence Therapeutics secured $20M+ including a recent $9.6M placement for its Accum platform enhancing ADCs in cancer. iDEL's dendrimer-based shuttle differentiates by offering tumor antigen-agnostic access compatible with diverse payloads.
Endosomal Traps Limit Oncology Drugs
Current therapies like ADCs and chemotherapeutics often fail due to endosomal entrapment, preventing cytosolic access to intracellular cancer drivers. This confines treatment to extracellular or membrane targets, leaving many oncogenes undruggable. Solid tumor patients face narrowed therapeutic windows as payloads degrade without reaching the cytosol.
Dendrimer Shuttle Unlocks Cytosolic Access
iDEL's proprietary platform uses a synthetic dendrimer shuttle for direct cytosolic transfer, evading endosomes via a unique pan-cancer uptake mechanism. It supports small molecules, large biologics, and nanobodies, broadening applications across indications. Unlike peptide-based systems, iDEL focuses on tumor-specific delivery without tissue-wide distribution.
As Marcus Kostka, PhD, Co-Founder and CEO noted:
"Our technology’s broad applicability to a range of drug classes harbors the potential to improve treatment outcomes for patients living with a range of high-need cancer indications."
Investors Back German Oncology Innovation
BiomedVC led the syndicate, joined by NRW.Venture, Gründerfonds Ruhr, and KHAN Technology Transfer Fund. This mix signals regional conviction in iDEL's platform, blending deep-tech VC with North Rhine-Westphalia government-backed funds. BiomedVC's focus on transformative oncology validates the shuttle's potential to shift paradigms.
As Aristotelis Nastos, PhD, Managing Partner at BiomedVC noted:
"iDEL Therapeutics’ concept to unlock new cancer treatments represents an exciting new opportunity with the potential to significantly impact the oncology landscape."
Intracellular Delivery Market Expands
The intracellular targeted drug delivery market reaches $7.9B by 2030 per Virtue Market Research, growing at 14% CAGR. Drivers include rising cancer incidence and demand for biologics accessing undruggable targets. Starpharma has raised $100M+ via public equity for dendrimer chemo delivery, while Entrada and Defence pursue similar cytosolic goals but with payload-specific limits.
Preclinical Leads Eye Clinic
With 2-10 employees since 2025 founding, iDEL exited stealth to prioritize its two leads: a nanobody conjugate and multicancer drug. Funds target preclinical advancement to clinical trials, positioning for partnerships amid ADC evolution.